Top of this page
Skip navigation, go straight to the content

Our Science Pipeline
 

PIPELINE

 

Our pipeline builds the basis of UCB’s future, so our focus is on breakthrough innovative approaches with the goal of developing new highly differentiated solutions that will significantly impact the lives of patients. We have developed unique partnerships with patients at every step of the clinical development process to identify needs and inform study design and operations.



  Indications Phase 1 Phase 2 Phase 3 Filing
bimekizumab (IL17AF)psoriasisphase 3
 psoriatic arthritisphase 3 half
 axial spondyloarthritis
phase 3 half
 hidradenitis suppurativa
phase 3 half
zilucoplan (C5)myasthenia gravisphase 3 half
 immune-mediated necrotizing myopathy (IMNM)phase 2 half
rozanolixizumab (FcRn)myasthenia gravisphase 3 half
 immune thrombocytopeniaphase 3 half
dapirolizumab pegol (CD40L)systemic lupus erythematosus1phase 3 half
Staccato® alprazolamactive epileptic seizurephase 2
bepranemab (UCB0107)
tauopathiesphase 1
6 Projects phase 1 half

1 In partnership with Biogen


Zilucoplan is also being assessed in:

  • COVID-associated ARDS by University of Ghent (Belgium), Medical Research Council (U.K.) & COMMUNITY Trial (U.S.)
  • amyotrophic lateral sclerosis (ALS) by HEALEY ALS Platform Trial